Meihua International Medical Technologies Co., Ltd. (MHUA) AI Stock Analysis

• Market Cap: $7.02M
• Dividend Yield: N/A
• Average Volume (3M): 258.45K
• Price to Earnings (P/E): 40.9
• Beta (1Y): 1.33
• Revenue Growth: -4.99%
• EPS Growth: -19.10%
• Country: US
• Employees: 619
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): 9.86
• Shares Outstanding: 559,045
• 10 Day Avg. Volume: 415,554
• 30 Day Avg. Volume: 258,455
• PEG Ratio: -0.05
• Price to Book (P/B): 0.06
• Price to Sales (P/S): 0.10
• P/FCF Ratio: 0.65
• Enterprise Value/Market Cap: 0.12
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: 0.03
• Enterprise Value/Ebitda: 0.06
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $8.00 ▲(18.34% Upside)

The overall stock score is primarily influenced by solid financial performance, despite challenges in cash flow stability. Technical analysis indicates bearish momentum, which negatively impacts the score. Valuation is moderate, but the lack of a dividend yield reduces its appeal to certain investors.

Positive Factors

Low Leverage

Low leverage enhances financial resilience, providing the company with greater flexibility to invest in growth opportunities without the burden of high debt.

Strategic Share Structure Changes

These changes aim to streamline the capital structure and enhance market positioning, potentially improving investor confidence and operational efficiency.

Leadership Changes

New leadership with strategic and international experience can enhance market positioning and operational strategies, fostering long-term growth.

Negative Factors

Revenue Decline

A decline in revenue indicates challenges in market demand or competitive positioning, potentially impacting long-term growth prospects if not addressed.

Nasdaq Delisting

Delisting from Nasdaq can reduce market visibility and investor confidence, potentially limiting access to capital and affecting stock liquidity.

Free Cash Flow Volatility

Volatile free cash flow can strain financial resources, limiting the company's ability to invest in growth initiatives and maintain operational stability.

Meihua International Medical Technologies Co., Ltd. Business Overview & Revenue Model

Company Description

Meihua International Medical Technologies Co., Ltd. (MHUA) is a leading provider of advanced medical technologies and solutions, specializing in the development and manufacturing of medical devices and equipment. The company operates primarily in the healthcare sector, focusing on innovative products that enhance patient care and improve clinical outcomes. Its core offerings include diagnostic tools, therapeutic devices, and hospital equipment, catering to a wide range of medical applications.

How the Company Makes Money

MHUA generates revenue through multiple key streams, primarily from the sale of its medical devices and equipment to hospitals, clinics, and healthcare providers. The company leverages a direct sales model coupled with distribution partnerships to reach a broader market. Additionally, MHUA may engage in research and development collaborations with healthcare institutions and other technology firms, potentially leading to licensing agreements or shared revenue from innovative products. Strategic partnerships with healthcare organizations and participation in government tenders for medical supplies further contribute to its earnings, ensuring a diverse and stable income foundation.

Meihua International Medical Technologies Co., Ltd. Financial Statement Overview

Summary

Meihua International Medical Technologies Co., Ltd. demonstrates solid financial health with stable revenue and robust operating performance. While leverage is low, enhancing financial resilience, the company faces challenges in maintaining consistent free cash flow. Overall, the financials indicate potential for growth if cash flow stability is improved.

Income Statement

The company has demonstrated consistent revenue generation with slight fluctuations. Gross profit margins remain stable, indicating efficient production or service delivery. However, net profit margins have declined, suggesting increased costs or lower efficiency in managing expenses. The EBIT and EBITDA margins are robust, reflecting strong operating performance.

Balance Sheet

The balance sheet shows a strong equity position with a favorable debt-to-equity ratio, indicating low leverage and financial stability. The return on equity has been positive, suggesting effective use of shareholder funds. However, the equity ratio has seen minor variations, reflecting changes in asset management.

Cash Flow

The cash flow statement reveals a significant improvement in operating cash flows in recent years, enhancing liquidity. Despite this, free cash flow has been volatile, occasionally negative, indicating challenges in managing capital expenditures and cash generation relative to net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	89.55M	96.91M	97.10M	103.35M	104.04M	89.06M
Gross Profit	30.64M	33.30M	33.09M	38.10M	39.81M	37.16M
EBITDA	12.91M	15.70M	15.77M	11.65M	27.03M	24.39M
Net Income	9.27M	10.84M	11.63M	6.24M	20.95M	19.05M
Balance Sheet
Total Assets	190.58M	186.24M	171.92M	163.58M	136.86M	106.05M
Cash, Cash Equivalents and Short-Term Investments	15.55M	15.96M	16.93M	26.74M	8.15M	7.19M
Total Debt	11.45M	7.95M	7.33M	6.81M	5.18M	3.22M
Total Liabilities	25.64M	27.26M	25.08M	24.90M	30.05M	21.31M
Stockholders Equity	164.95M	158.98M	146.33M	138.12M	106.81M	84.74M
Cash Flow
Free Cash Flow	3.59M	14.50M	-2.41M	-11.86M	-904.89K	-10.79M
Operating Cash Flow	3.72M	14.64M	2.28M	-9.16M	-54.66K	5.33M
Investing Cash Flow	-2.82M	-20.42M	-12.46M	-8.62M	-833.82K	-16.09M
Financing Cash Flow	6.70M	6.21M	706.13K	37.25M	1.86M	1.71M

Meihua International Medical Technologies Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 6.76
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For MHUA, the sentiment is Negative. The current price of 6.76 is below the 20-day moving average (MA) of 9.68, below the 50-day MA of 19.81, and below the 200-day MA of 33.64, indicating a bearish trend. The MACD of -4.22 indicates Negative momentum. The RSI at 22.84 is Positive, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MHUA.

Meihua International Medical Technologies Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MHUA	58 Neutral	$7.02M	40.95	5.90%	―	-4.99%	-19.10%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
POAI	47 Neutral	$14.46M	-0.04	―	―	-47.20%	-163.70%
EKSO	44 Neutral	$17.88M	-0.95	-85.01%	―	-16.59%	43.20%
WOK	41 Neutral	$54.70K	―	―	―	―	―
LUCY	35 Underperform	$7.49M	-0.51	-74.10%	―	53.22%	72.69%
GCTK	28 Underperform	$4.19M	>-0.01	―	―	―	60.83%

Meihua International Medical Technologies Co., Ltd. Corporate Events

Meihua International Medical Technologies Announces Major Share Structure Changes

On November 8, 2025, Meihua International Medical Technologies Co., Ltd. held an extraordinary general meeting where shareholders approved several significant changes to the company’s share structure. The resolutions included a consolidation of every 100 ordinary and preferred shares into one consolidated share, an increase in authorized share capital to $500 million, and the creation of new classes of shares. These changes aim to streamline the company’s capital structure and potentially enhance its market positioning, reflecting strategic adjustments that could impact stakeholders and future operations.

Meihua International Medical Technologies Announces Extraordinary General Meeting for Share Restructuring

Meihua International Medical Technologies Co., Ltd. has announced an extraordinary general meeting of shareholders scheduled for November 8, 2025. The meeting will address several key resolutions, including a share consolidation, an increase in authorized share capital, and the adoption of a 2025 Equity Incentive Plan. These changes are aimed at restructuring the company’s share capital and enhancing its operational framework, potentially impacting shareholder value and company governance.

Meihua International Medical Technologies Secures $15.2 Million Through Private Placement

On October 8, 2025, Meihua International Medical Technologies Co., Ltd. entered into a securities purchase agreement with non-U.S. investors to sell up to 40 million ordinary shares at $0.38 per share, aiming to raise $15.2 million. The proceeds are intended for working capital and general corporate purposes, potentially strengthening the company’s financial position and operational capabilities. This private placement could enhance Meihua’s market presence and provide additional resources for strategic initiatives.

Meihua International Announces Leadership Changes

On September 30, 2025, Meihua International Medical Technologies Co., Ltd. announced significant changes in its board of directors. Mr. Yongjun Liu resigned as chairman and Mr. Xiaoming E stepped down as an independent director, both for personal reasons. The company appointed Ms. Ailiang Wang as the new Chairwoman and Mr. Chongbo Gao as an independent director. These appointments are expected to bring strategic leadership and international experience to the company, potentially enhancing its market positioning and operational strategies.

Meihua International Medical Technologies Releases Mid-2025 Financial Results

Meihua International Medical Technologies Co., Ltd. has released its unaudited financial statements for the six months ending June 30, 2025. The company reported a decrease in total revenues compared to the previous year, with a total of $37.98 million in 2025 compared to $45.34 million in 2024. Despite the revenue drop, the company managed to maintain a positive income from operations, although it was lower than the previous year. This financial update may impact the company’s market positioning and stakeholder confidence as it reflects challenges in maintaining revenue growth.